week one textbook notes
Nursing practice in Canada and drug therapy
Context: Canadian nursing practice is shaped by aging population, increased patient acuity/complexity, rising drug therapies (including natural health products and OTCs), costs, shortages, and technology. Nurses must know drugs, adverse effects, interactions, and practice safe medication administration.
Objectives (from Chapter start):
List the five phases of the nursing process.
Describe the assessment process for patients receiving medications (subjective and objective data).
Formulate nursing diagnoses related to pharmacotherapy.
Identify goals and expected patient outcomes.
Understand evaluation in medication administration aligned with goals/outcomes.
Develop collaborative plans of care using the nursing process and medication administration principles.
List and discuss the Ten Rights of safe medication administration.
Discuss professional responsibilities/standards of practice for medication administration.
Key terms (highlights):
Adherence: patient involvement in treatment; active, voluntary, collaborative.
Critical thinking: reasoning to understand/solve problems; foundation of nursing process; supported by best evidence.
Evidence-informed practice (EIP): explicit consideration of best evidence to guide decisions among health team, patient, and family.
Expected patient outcomes: specific, observable patient behaviors/resulting from nursing diagnoses.
Goals: time-specific, describe generally what must be accomplished for a nursing diagnosis.
Medication error: any preventable adverse drug event involving inappropriate medication use.
Nonadherence: informed patient decision not to follow plan.
Nursing process: assessment, nursing diagnoses, planning (goals/outcomes), implementation (with patient teaching), evaluation.
Prescriber: licensed health professional who can prescribe meds.
Overview of the professional nursing environment in Canada
Increased accountability and emphasis on safe medication practices.
Importance of critical thinking and clinical reasoning in selecting therapeutic options and ensuring safety.
The nursing process as a framework
A five-phase, flexible, research-supported framework: assessment, nursing diagnoses, planning, implementation, evaluation.
Used to deliver individualized, thorough care, including pharmacotherapy.
Some institutions view it as controversial or foundational to practice depending on the framework used, but it remains a major systematic framework.
Assessment: data collection for pharmacotherapy
Sources: patient, family, caregiver, chart, labs, diagnostic tests, physical/clinical assessments.
Data types: subjective (spoken concerns, reported symptoms) and objective (vital signs, lab values, exam findings).
Examples of objective data for med assessment: age, height, weight, allergies, med profile, health history.
Assessment content includes drug actions; signs/symptoms of allergic reactions; adverse effects; dosages/administration routes; contraindications; drug–drug, drug–food, and drug–laboratory interactions; antidotes; and toxicities.
Use current references (e.g., CPS, drug inserts, drug handbooks, Health Canada Drug Product Database, RxFiles).
Assessment questions example: intake, swallowing ability, labs (kidney/liver function), blood pressure, pulse, temperature, current meds, adherence issues, prior experiences with regimens, traditional remedies, age-related considerations.
The nursing diagnoses process (Box-like guidance in the text)
Nursing diagnoses are professional conclusions about how a patient responds to health conditions or medications.
Nursing diagnoses for drug therapy emerge from data related to inadequate knowledge; risk of injury; nonadherence; bodily function disturbances; or other drug-related concerns.
NANDA-I and ICNP frameworks provide standardized language for diagnoses; ICNP supports interprofessional vocabularies; CNA endorses ICNP.
Three-part formulation guidance:
Part I: human response (Deficient knowledge, readiness for enhanced knowledge, etc.).
Part II: related factors (e.g., lack of experience with regimen, literacy level).
Part III: cues/evidence (e.g., inability to demonstrate, reports of adverse effects).
Prioritization: actual responses ranked above risk; ABCs (airway, breathing, circulation) often guide prioritization.
Case guidance: example nursing diagnosis for anemia related to iron therapy includes related factors and evidentiary clues.
Planning: goals and expected patient outcomes
Identify short-term and long-term goals; set time frames; goals must be objective, realistic, measurable, and patient-centered.
Expected outcomes are specific descriptions of patient goals tied to each nursing diagnosis.
Outcomes address special storage/handling, administration procedures, required equipment, drug interactions, adverse effects, contraindications.
Planning phase enables resource acquisition and procedural review to ensure safe care.
Implementation: actions and patient involvement
Guided by assessment/diagnoses/planning; requires ongoing communication and collaboration with patient, family, and health team.
Interventions can be independent, collaborative, or dependent on prescriber orders.
Interventions must include details like frequency and instructions; address drug-specific considerations (e.g., dose timing and monitoring).
In medication administration, informed consent/choice should underpin decisions.
Nurses are advocates for marginalized patients facing barriers to care (drug coverage, access, affordability).
Ten Rights of medication administration: historically five rights expanded to ten to promote patient safety; detailed in Box 1.2 (see below).
Introduction of electronic health records (EHRs) and related security/privacy considerations.
Evaluation: monitoring and revising care
Evaluation = ongoing assessment of whether goals and outcomes are met, including therapeutic effects, adverse effects, toxicity, and overall drug response.
Documentation of evaluation is critical; if goals are met, plan may be revised; if not met, the entire plan may be revised.
Ten Rights of Medication Administration (Box 1.2)
1) Right Drug (Right Medication)
2) Right Dose
3) Right Time
4) Right Route
5) Right Patient
6) Right Reason
7) Right Documentation
8) Right Evaluation (Right Assessment)
9) Right Patient Education
10) Right to RefuseExpanded patient safety considerations and additional rights/risks
The Rights emphasize patient safety, accurate education, system analysis, proper storage, dosage accuracy, order transcription checks, correct administration routes, special situations (e.g., NGT use, unconscious patients, geriatrics), and error prevention.
Provincial/territorial regulations and agency policies may add or modify rights; rights are patient-centered, not solely system-focused.
The right drug and system checks
The RN is responsible for verifying orders; UCPs can assist but the RN remains accountable.
Best practice: prepare meds close to administration time; avoid letting others administer on your behalf unless under rare exceptions (mass immunization, emergencies).
Three checks for right drug/name/expiry: during preparation, at bedside, and at removal from the drawer/stock.
Use of generic names to minimize confusion due to trade names or look-alike names; be mindful of look-alike/sound-alike (LASA) risks.
Evidence-informed practice and patient safety
Five Rights were found insufficient due to system factors; nurses should embrace seven or ten rights, including drug history, assessment, risk anticipation, patient education, and evaluation.
Technology (texting, emails, wireless) introduces new risks; protect information with encryption/passwords and agency policies; avoid breaches of confidentiality.
Evidence in practice: ISMP and CMS context
Case: Five Rights’ limitations highlighted by studies (e.g., Martyn et al., 2019) show inconsistent use; emphasis on organization and patient-centered care.
Emphasis on a systems approach to medication safety; include patient involvement and a move toward a “just culture” that emphasizes learning and remediation over blame.
Box 1.3: Guidelines for timely administration of medications
Time-critical medications: administer exactly on time when necessary; otherwise within 30 minutes before/after the scheduled time.
Non-time-critical medications: administer within 2 hours before/after the scheduled time.
Stat meds must be given within 30 minutes of the order.
Evidence-informed practice and technology integration
EHRs and barcoding reduce errors; ensure privacy and security; follow institution-specific policies for transmission of orders (email, texting, etc.).
BOX 2.1–2.3 (pharmacology foundations; dosage forms and first-pass effects)
Drug routes and dosage forms dramatically affect absorption and onset of action; certain forms (enteric-coated, sustained-release) have unique considerations (e.g., not crushing enteric-coated forms).
A drug’s route determines its exposure and bioavailability; IV route provides 100% bioavailability; oral bioavailability is reduced by first-pass metabolism in the liver.
Sublingual and buccal routes bypass first-pass metabolism; enteral vs parenteral comparisons.
Pharmacological principles (Chapter 2): overview
Core aims and vocabularies
Pharmacology includes pharmaceutics, pharmacokinetics (ADME), pharmacodynamics (drug–receptor interactions), pharmacogenetics, pharmacoeconomics, pharmacotherapeutics, pharmacognosy, and toxicology.
Pharmacology definitions:
Pharmaceutics: dosage form design and pharmaceutical properties affecting dissolution/absorption.
Pharmacokinetics (ADME): what the body does to a drug.
Pharmacodynamics: what the drug does to the body (mechanisms of action).
Drug names and classifications
Three names during development: chemical name, generic name (nonproprietary), and trade name (proprietary).
Trade names are often market-driven; generic names reduce medication errors due to name similarity.
Therapeutic drug substitution requires evidence of therapeutic equivalence (same effect), often after patent expiry when generics enter the market.
Phases of pharmacology
Pharmaceutics (dosage form design) → Pharmacokinetics (ADME) → Pharmacodynamics (drug–target interactions).
The pharmacology phases are often depicted as a sequence: pharmaceutical phase → pharmacokinetic phase → pharmacodynamic phase.
Regulation and labeling
Health Canada regulates drugs under the Food and Drugs Act and Regulations; off-label use (not Health Canada-approved indications) may occur with clinical judgement.
Toxicology, pharmacognosy, and other subspecialties are integrated into pharmacology education.
Drug development and regulation (INDs and submissions)
Investigational New Drug (IND) process, New Drug Submissions, and regulatory reviews; informed consent is essential for human trials.
Pharmaceutics: dosage forms and dissolution
Drug dissolution rate affects absorption; examples: liquids absorb faster than capsules/tablets; enteric-coated tablets resist stomach acid and dissolve in the intestines; particle size affects dissolution rate (e.g., micronized fenofibrate).
Injectable forms can be formulated to reduce toxicity (liposomal formulations).
Combination dosage forms exist (e.g., atorvastatin/amlodipine).
Dosage forms and routes (Table 2.2, 2.3 summary)
Enteral: tablets, capsules, elixirs, suspensions, solutions, suppositories (parenteral/rectal as forms), topical forms (ointments, creams, patches), inhalation, transdermal, etc.
Parenteral: injections (IV, IM, subcutaneous, intradermal, intrathecal, intra-arterial) with safety considerations (pH, sterility, injection technique).
Topical routes include skin, eyes, ears, nose, lungs, rectal, vaginal; transdermal patches provide systemic effect with constant delivery.
Absorption, distribution, metabolism, excretion (ADME)
Absorption: movement from administration site into bloodstream; bioavailability (fraction reaching systemic circulation).
First-pass effect: hepatic metabolism reduces systemic bioavailability for many orally administered drugs.
IV route = 100% bioavailability; oral routes vary (<100%). Sublingual/buccal bypass first-pass.
Distribution: drug transport via bloodstream to tissues; protein binding (albumin) affects free (active) drug fraction; volume of distribution (Vd) conceptually describes distribution across compartments; highly lipophilic drugs distribute widely into fat; hydrophilic drugs stay in extracellular fluid.
Metabolism: liver is primary site; cytochrome P450 enzymes mediate many transformations; enzyme inhibitors/inducers alter metabolism; genetic factors influence metabolism (pharmacogenetics).
Excretion: primarily renal (glomerular filtration, active tubular secretion/reabsorption); biliary/fecal excretion; enterohepatic recirculation can prolong drug action; kidney dysfunction requires dose adjustments; half-life and steady-state concepts guide dosing.
Pharmacokinetic concepts and equations (LaTeX syntax)
Half-life: is the time for serum drug concentration to fall by 50% during elimination.
Steady state: approximately reached after of regular dosing.
Bioavailability: fraction of administered dose reaching systemic circulation; intravenous administration yields (or 100%).
Volume of distribution: conceptual volume that would be required to contain the total amount of drug at the same concentration as in plasma;
often discussed as a diffusion into compartments.
Pharmacodynamics: drug actions at sites of activity
Receptor interactions: agonists activate receptors; antagonists inhibit; partial agonists elicit partial responses.
Receptor affinity: strength of drug binding to receptor; higher affinity = greater potential response.
Enzyme interactions: drugs may inhibit or enhance enzymes, altering metabolism of substrates.
Nonselective interactions: drugs affect membranes or cellular processes without receptor/enzyme specificity.
Therapeutic effect: desired pharmacologic effect; toxicity occurs when adverse effects exceed beneficial effects.
Drug–drug, drug–food interactions and pharmacokinetics
Drug interactions can affect absorption, distribution, metabolism, or excretion (ADME) and may be additive, synergistic, or antagonistic;
Examples include antacids reducing absorption of fluoroquinolones, or cytochrome P450 interactions affecting metabolism.
Therapeutic drug monitoring is used for drugs with narrow therapeutic windows and variable metabolism (e.g., warfarin, vancomycin, aminoglycosides).
Special dosage forms and considerations
Time-release/extended-release forms identified by abbreviations like SR, SA, CR, XL, XT; extending dosing intervals can improve adherence but must not be crushed (to avoid rapid release and toxicity).
Enteric-coated tablets should not be crushed (designed to protect gastric mucosa); some forms can be sprinkled on soft foods or opened for specific administration (consult pharmacist).
High-alert medications and safety
ISMP lists high-alert meds (e.g., insulin, anticoagulants, chemo agents, concentrated electrolyte solutions, opioids); require special handling to prevent MEs.
SALAD and LASA naming issues contribute to preventable errors; TALLman lettering can help differentiate look-alike names.
Pharmacology across the lifespan
Pediatric pharmacology emphasizes weight-based dosing, often via mg/kg, with BSA nomograms (West nomogram) for certain drugs; organ maturity affects dosing and safety.
Neonates/infants have unique absorption/distribution/metabolism/excretion and special care in dosing.
Older adults show altered ADME due to aging (reduced liver/kidney function, altered body composition, polypharmacy); Beers Criteria guide safer prescribing in older adults; careful monitoring and dose adjustment are essential.
Ethnocultural factors influence drug response (ethnopharmacology); genetic polymorphisms (e.g., acetylator status) affect metabolism; culture influences health beliefs, adherence, and communication needs.
Pregnancy and lactation pharmacology
Drug properties, gestational stage, and maternal factors influence fetal exposure.
Pregnancy safety labeling in Canada and the U.S. provides risk summaries, clinical considerations, and data for pregnancy and lactation.
Lactation: drug transfer into breast milk depends on fat solubility, molecular weight, ionization; decision-making requires risk–benefit analysis for mother-infant pair.
Pharmacotherapy planning and evaluation across lifespan
Therapy should consider maintenance, acute, supplemental, palliative, or empirical approaches; monitoring for efficacy and toxicity is essential.
Ethnocultural and life-span considerations in pharmacology
Ethnocultural considerations (ethnopharmacology)
Population diversity in Canada affects drug response due to genetics, diet, cultural beliefs, and traditional practices.
Glucose-6-phosphate dehydrogenase (G6PD) deficiency is a common example of ethnocultural pharmacogenetics; certain drugs should be avoided in G6PD deficiency (e.g., nitrofurantoin, primaquine).
Pharmacogenetic variations (e.g., slow vs. ultra-rapid acetylators) influence drug metabolism (isoniazid example); cytochrome P450 enzyme activity varies by ethnicity (e.g., certain Asian populations as poor metabolizers; some White populations as ultrarapid metabolizers).
Indigenous health beliefs and the medicine wheel reflect holistic views of health; traditional healing practices (e.g., smudging, ceremonies) may influence treatment decisions; clinicians should respect and integrate cultural values.
Ethnocultural factors influence health literacy, language, access to care, and adherence; culturally competent education is essential.
Special populations: Children and neonates
Pediatric dosing is complex due to body composition, organ maturity, and variable metabolism.
Volume of distribution and clearance differ from adults; first-pass metabolism in the immature liver is reduced.
Dosing tips: mg/kg is common; BSA nomograms are used for high-risk regimens (e.g., chemotherapy).
Pediatric dosing must account for organ maturity, weight, height, and development.
Special populations: Older adults
Age-related physiological changes affect pharmacokinetics: decreased hepatic metabolism, reduced renal function, reduced total body water, increased fat stores, and diminished albumin production.
Polypharmacy and age-related comorbidity raise the risk of interactions and adverse effects; start low and go slow; monitor eGFR and adjust dosing accordingly.
Beers Criteria identifies potentially inappropriate medications for older adults; differential risk across ethnic groups may exist; polypharmacy mitigation strategies including deprescribing and medication reconciliation are important.
Pregnancy and lactation considerations
Pregnancy safety categories help decide drug use during pregnancy; risk–benefit analysis is essential; lactation considerations require evaluating infant exposure via breast milk.
Pharmacology in practice: timing, routes, interactions, and safety
Drug interactions and pharmacokinetic phases (Table 2.9 overview)
Absorption: e.g., antacid with levofloxacin reduces absorption; reduced efficacy.
Distribution: warfarin with amiodarone increases free drug levels due to competition for protein binding.
Metabolism: erythromycin with cyclosporine reduces metabolism of cyclosporine, risking toxicity.
Excretion: amoxicillin with probenecid delays renal excretion, increasing plasma levels.
Drug interactions can be harmful or beneficial; significant interactions require dosage or therapy adjustments.
Drug indications, toxicology, and safety
Therapeutic index: ratio of toxic level to therapeutic level; a low TI means closer monitoring is needed.
Toxicology: management of poisons; antidotes for common substances listed (e.g., acetaminophen with acetylcysteine; digoxin with digoxin antibodies).
Therapeutic drug monitoring and pharmacokinetic/pharmacodynamic concepts in practice
Peak and trough levels are used to ensure adequate exposure and avoid toxicity for certain drugs (e.g., aminoglycosides, vancomycin).
Time to onset, peak effect, and duration of action influence dosing schedules and monitoring strategies.
Drug administration routes and considerations
Enteral (GI tract) vs Parenteral vs Topical
Enteral routes rely on gastric/intestinal environment; first-pass effect through liver reduces bioavailability; tablets, capsules, solutions, suspensions, suspensions, and enteric-coated forms differ in dissolution/absorption.
Parenteral routes (IV, IM, subcutaneous, intradermal, intrathecal, intra-arterial) bypass or minimize first-pass metabolism; provide rapid or depot effects; require sterile technique and careful monitoring.
Topical/transdermal/aerosol routes deliver local or systemic effects; transdermal patches provide steady drug delivery; inhalation provides rapid local pulmonary effects.
Box 2.2: First-pass effects and routes
Non–first-pass routes include sublingual, buccal, transdermal, inhalation, IV, intramuscular.
Enteral routes (oral, sublingual) involve hepatic first-pass for many drugs; rectal routes may have mixed first-pass.
Box 2.3: Nursing considerations for routes
IV: rapid onset, precise control; but higher costs, infection risk, potential for overdose and embolism; requires monitoring and line care.
IM: good for poorly soluble drugs or depot formulations; slower onset than IV; site selection and needle size are important.
Subcutaneous: slower absorption, good for insulin and heparin; site selection and angle of injection matter.
Oral: convenient and safer; absorption variability; affected by gastric pH and presence of food; instructions about timing with meals matter.
Sublingual/buccal: rapid absorption, bypasses liver, rapid onset.
Rectal: useful when oral administration not possible; absorption is erratic but can provide systemic effects.
Topical and transdermal: localized vs systemic effects; skin integrity affects absorption; patch rotation important to prevent irritation.
Practical aspects of dose forms and administration
Extended-release formulations must not be crushed; enteric-coated tablets should not be crushed.
For patients with swallowing difficulties, some formulations can be opened or mixed with soft foods but should be verified with a pharmacist.
Crushing or splitting certain dose forms can cause toxicity or loss of efficacy; check with pharmacology references.
Military time is standard in many clinical settings; avoid abbreviations that could cause dosing errors (e.g., “u” for units).
Safety, ethics, and law in pharmacology
Adverse drug events and reactions
ADE: any undesirable event related to drug use (preventable or not).
ADR: undesired response at therapeutic dosages; types include pharmacological reactions (extension of drug effect), hypersensitivity (immune-mediated), idiosyncratic (genetically determined unusual response), and drug interactions.
Distinction: ADEs can be due to error or inherent drug effects; ADRs are drug-related biological responses.
Medication errors (MEs)
MEs: preventable events during any stage of the medication-use process (prescribing, transcribing, dispensing, administering, monitoring).
High-alert medications require special safety measures due to potential harm (e.g., insulin, anticoagulants, concentrated electrolytes, chemotherapy).
LASA and SALAD naming issues contribute to MEs; TALLman lettering is a strategy to reduce confusion.
A systems approach (beyond the individual nurse) is essential; just culture emphasizes learning and system improvements.
Disclosing medication errors and patient safety culture
Disclosure/communication with patients about errors; apology legislation exists in several provinces to protect apologies from being used as admissions of fault.
Institutional policies encourage reporting of MEs and near-misses to improve safety.
Legal and ethical principles in pharmacology
Federal and provincial/territorial laws govern practice; nurse practice acts delineate scope, standards, and responsibilities.
Privacy laws (PIPEDA, PHIPA in Ontario, and BC equivalents) govern handling of personal health information; confidentiality and privacy are critical in pharmacology practice.
Informed consent and ethical conduct: clinical trials require informed consent; placebo ethics require careful communication and patient protection.
Be mindful of placebo use in research vs. standard care; ensure transparency and patient rights.
Disclosures and ethics in pharmacology
Ethical principles guiding practice: autonomy, beneficence, nonmaleficence, justice, fidelity, veracity, confidentiality.
ICN and CNA codes provide global and national frameworks for ethical practice; nurses must balance patient autonomy with professional responsibilities.
Drug legislation in Canada (legal framework overview)
Food and Drugs Act (federal) and Food and Drug Regulations; Controlled Drugs and Substances Act (CDSA).
Drug Identification Number (DIN) system; prescription and OTC drug regulation; product labelling and safety standards.
Special Access Programme (SAP) for compassionate access to drugs not yet approved for sale in Canada.
Privacy laws: PIPEDA (federal) and provincial health information acts (e.g., PHIPA in Ontario, BC privacy legislation). Electronic health records and data confidentiality are central concerns.
Health Canada regulates drug development, approval, labeling, and safety monitoring; inspectors enforce compliance.
Nursing accountability and professional liability
Nurses must be prepared to defend practice and maintain professional liability coverage; local nurse associations provide guidance and risk-management resources.
Documentation and incident reporting: detailed, non-judgemental, objective notes; do not include incident reports as part of the medical record; use incident reports for risk management purposes.
The importance of continuing education, practice standards, and institutional policies in safeguarding practice.
Patient education and teaching (patient education across the lifespan)
The essential role of patient education in safe drug administration and adherence; patient education is part of the nursing process and an essential professional responsibility.
Domains of learning: cognitive (knowledge), affective (feelings/values), psychomotor (skills).
Use of Box 7.1–7.4 strategies for effective patient education: assess learning needs; simplify information; provide materials at an appropriate reading level; consider language and culture; involve family; use multiple modalities (print, video, demonstrations); teach-back method to confirm understanding; document educational content and patient responses; plan discharge teaching with support for ongoing learning.
Health literacy: significant determinant of patient outcomes; strategies include using plain language materials, visual aids, checking comprehension, and providing culturally appropriate resources.
Discharge planning: ensure a comprehensive discharge plan; provide drug information, follow-up appointments, and resources; use teach-back to confirm understanding.
Case-related notes and practical examples (highlights pulled from transcript)
Example case prompts and discussion prompts are embedded throughout the text to illustrate how the nursing process, pharmacology principles, and ethical/legal considerations play out in practice (e.g., Case studies on anemia management, nitroglycerin therapy, and clinical trials).
Example exam-style questions (examination review questions) focus on applying nursing process steps, recognizing drug-dose calculations, recognizing route implications, and applying Ten Rights with real-world scenarios.
Evidence in practice boxes and scenarios emphasize that medication safety requires more than memorizing rights; a systems approach, critical thinking, and interprofessional collaboration are essential to minimize errors.
Quick reference highlights (LaTeX-ready formulas you may want to cite in notes)
Therapeutic index:
Half-life and steady state: ; steady state reached after approximately
Bioavailability: fraction of administered dose reaching systemic circulation; intravenous administration yields (100%)
Pharmacokinetic compartments and distribution concepts can be expressed via Volume of Distribution (Vd) and free (unbound) drug fraction; protein binding is critical to pharmacodynamics and toxicity risk
Key takeaways
The nursing process provides a comprehensive framework for safe, evidence-informed medication administration, with emphasis on critical thinking, patient involvement, and collaboration.
The Ten Rights (and expanded considerations) serve as foundational, but insufficient alone; a systems approach that includes comprehensive drug history, interactions, and patient education is essential.
Pharmacology principles (pharmaceutics, pharmacokinetics, pharmacodynamics) explain how dosage forms, routes, metabolism, and excretion influence drug effects and safety across lifespan.
Special populations (pediatrics, older adults, ethnocultural groups, pregnancy/lactation) require tailored dosing, monitoring, and education to minimize risk and maximize therapeutic benefit.
Safety and ethics are woven throughout: informed consent, confidentiality, transparency in error disclosure, and a focus on safe practice through standards, guidelines, and Beers Criteria where applicable.
Ongoing professional development, adherence to legislation, and evidence-informed practice are essential to safe, ethical pharmacology nursing in Canada.